JSMD194 (formerly LY3039478) is a small molecule Gamma-Secretase Inhibitor being investigated in clinical trials in patients with T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma and multiple myeloma.
|Developed By||Eli Lilly and Company|
|Additional Names||LY3039478, JSMD194|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.